Handok pharmaceuticals got approval of Phase 1 clinical trial for their first self-developed anti-inflammatory medication for autoimmune disease
Handok pharmaceuticals (Chairman Kim, Young-Jin) got approval of Phase 1 clinical trial for their first self-developed anti-inflammatory medication for autoimmune disease 'HL2351', from Minister of Food and Drug Safety. This is Handok's first approved biopharmaceuticals developed through open Inn...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
